Close Menu

NEW YORK (GenomeWeb) – Bio-Rad Laboratories has received clearance from the US Food and Drug Administration for its first liquid biopsy assay and Droplet Digital PCR system for diagnostic use, the firm announced today.

The test is designed for monitoring treatment response in chronic myeloid leukemia and is also the first-ever digital PCR product to receive FDA clearance, according to the company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.